APA (7th ed.) Citation

Lee, E. Q., Zhang, P., Wen, P. Y., Gerstner, E. R., Reardon, D. A., Aldape, K. D., . . . Mehta, M. P. (2020). NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer (0008543X), 126(12), 2821. https://doi.org/10.1002/cncr.32811

Chicago Style (17th ed.) Citation

Lee, Eudocia Q., et al. "NRG/RTOG 1122: A Phase 2, Double-blinded, Placebo-controlled Study of Bevacizumab with and Without Trebananib in Patients with Recurrent Glioblastoma or Gliosarcoma." Cancer (0008543X) 126, no. 12 (2020): 2821. https://doi.org/10.1002/cncr.32811.

MLA (9th ed.) Citation

Lee, Eudocia Q., et al. "NRG/RTOG 1122: A Phase 2, Double-blinded, Placebo-controlled Study of Bevacizumab with and Without Trebananib in Patients with Recurrent Glioblastoma or Gliosarcoma." Cancer (0008543X), vol. 126, no. 12, 2020, p. 2821, https://doi.org/10.1002/cncr.32811.